Skip to search formSkip to main contentSkip to account menu

eltrombopag

Known as: Eltrombopagum, eltrombopag [Chemical/Ingredient] 
An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet… 
National Institutes of Health

Related topics

Related topics

18 relations

Broader (3)

BenzoatesHydrazinesPyrazoles
Breast Cancer Resistance Protein Inhibitors [MoA]Eltrombopag olamineMPL protein, humanThrombopoietin Receptor Agonists [MoA]

Narrower (3)

PromactaRevoladeSB-497115-GR

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting
ABSTRACT Objective: The thrombopoietin mimetic eltrombopag has been used in clinical trials for the frontline and salvage… 
2017
2017
Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia
Review
2013
Review
2013
Severe cutaneous toxicity related to Eltrombopag
Baliga, B.S., Haynes, Jr, J., Obiako, B. & Mishra, N. (2010) Combined effects of arginine and hydroxyurea on BFU-E derived colony… 
Review
2012
Review
2012
ROMIPLOSTIM AND ELTROMBOPAG FOR IMMUNE THROMBOCYTOPENIA: METHODS FOR INDIRECT COMPARISON
Objectives: Immune thrombocytopenia (ITP) causes increased platelet destruction and suboptimal platelet production, increasing… 
2010
2010
Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP
Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP 
2008
2008
Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE)
INTRODUCTION: Eltrombopag (PROMACTA®/REVOLADE®; GlaxoSmithKline, Collegeville, PA, USA) is a first-in-class, oral, small molecule… 
2008
2008
Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia
After many decades of an orphan existence, immune thrombocytopenic purpura is a central focus for the clinical development of… 
2008
2008
Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura.
INTRODUCTION: Eltrombopag (PROMACTA®/REVOLADE®; GlaxoSmithKline, Collegeville, PA) is the first oral, small molecule, non-peptide… 
Review
2007
Review
2007
Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection
Background  Patients with chronic liver disease and hepatitis C virus (HCV) frequently experience thrombocytopenia that… 
Review
2007
Review
2007
New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review
Background  Patients with chronic immune thrombocytopenic purpura (ITP) only require treatment if they are bleeding, or prior to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)